VHVedat Hamuryudan

Vedat Hamuryudan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vedat Hamuryudan has a total of 207 co-authors. Here are the top co-authors by number of shared publications:

  • Emire Seyahi

    Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye

    22 shared publications
  • Gulen Hatemi

    Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye

    21 shared publications
  • Izzet Fresko

    Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye

    19 shared publications
  • Emire Seyahi

    Division of Rheumatology, Department of Internal Medicine, School of Medicine, and Behçet’s Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey

    18 shared publications
  • Serdal Ugurlu

    Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine Istanbul University‐Cerrahpasa Istanbul Turkey

    17 shared publications
  • Sinem Nihal Esatoglu

    Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa , Istanbul, Türkiye

    16 shared publications

Latest Publications

  • Drug survival of adalimumab across different manifestations of Behçet’s syndrome: a retrospective analysis in 335 patients

    by Ozge Sonmez, Sinem Nihal Esatoglu, Didar Ucar, Elif Kaymaz, Yesim Ozguler, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Ugur Uygunoglu, et al.

    Objectives: Studies on drug survival provide real-world data on efficacy as well as safety. We aimed to evaluate the long-term drug survival of adalimumab (ADA) in a large cohort of patients with Behçet’s syndrome (BS). Methods: We conducted a retrospective chart review of 335 BS patients who started ADA between 2008 and 2023. All treatment discontinuations were considered as events, regardless of the underlying reason, to reflect overall treatment persistence in a real-world setting. Results: ADA retention rates at 6, 12 and 24 months were 88.9%, 78.3% and 67.1%, respectively. Over a mean follow-up of 26.6 (23) months, 137 patients (41%) discontinued ADA. The most common reason for discontinuation was inefficacy, followed by adverse events, non-compliance, remission and other reasons. No significant associations were observed between treatment discontinuation and age, sex, disease duration, prior tumour necrosis factor inhibitor exposure, concomitant disease-modifying antirheumatic drug use or major organ involvement. Dose interval extension was performed in 36 patients, with relapse or flare occurring in five (14%), all of whom achieved remission after dose re-adjustment. Dose intensification was applied in 30 patients, resulting in remission in 17 (56.6%). Conclusion: ADA showed a good retention rate at month 6, followed by a gradual decline in drug retention over time. Secondary inefficacy was the most common reason for treatment discontinuation, followed by adverse events and non-compliance, whereas primary inefficacy was uncommon. Dose intensification to achieve active disease control and dose de-escalation in patients with sustained remission may be feasible management strategies.

  • Behçet's syndrome: one year in review 2026

    by Gülen Hatemi, Emire Seyahi, Izzet Fresko, Rosaria Talarico, Didar Uçar, Vedat Hamuryudan

    Review; Authors: G. Hatemi, E. Seyahi, I. Fresko, R. Talarico, D. Uçar, V. Hamuryudan

  • Behçet's syndrome: one year in review 2025

    by Gülen Hatemi, Emire Seyahi, Izzet Fresko, Rosaria Talarico, Didar Uçar, Vedat Hamuryudan

    Review; Authors: G. Hatemi, E. Seyahi, I. Fresko, R. Talarico, D. Uçar, V. Hamuryudan


  • Behçet's syndrome: one year in review 2024

    by Gülen Hatemi, Emire Seyahi, Izzet Fresko, Rosaria Talarico, Didar Uçar, Vedat Hamuryudan

    One year in review; Authors: G. Hatemi, E. Seyahi, I. Fresko, R. Talarico, D. Uçar, V. Hamuryudan


  • De novo manifestations during adalimumab treatment in Behçet’s syndrome

    by Sinem Nihal Esatoglu, Ozge Sonmez, Didar Ucar, Elif Kaymaz, Yesim Ozguler, Serdal Ugurlu, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Vedat Hamuryudan, et al.

    Objectives: Treatment response may be variable across organ manifestations of Behçet’s syndrome (BS). We aimed to determine the frequency of de novo manifestations during adalimumab treatment. Methods: We conducted a chart review of all BS patients who received adalimumab in our centre between 2008 and 2023. Demographic data, reasons for initiating adalimumab, concurrent medications, previous treatments, and outcomes were recorded. We defined de novo manifestations as new BS manifestations that occurred for the first time during treatment with adalimumab. For patients with vascular involvement, a new vascular event at another vessel was also considered as a de novo manifestation. Results: Among the 335 patients, a de novo manifestation developed in 14 (4%) patients. De novo manifestations were vascular involvement in five patients, arthritis in three, anterior uveitis in two, nervous system involvement in two, gastrointestinal involvement in one, and epididymitis in one patient. The primary reasons for adalimumab treatment were vascular involvement in five patients, uveitis in four, arthritis in three, mucocutaneous involvement in one, and epididymitis in one patient. Upon the development of de novo manifestation, adalimumab was switched to another biologic in four patients, dose was intensified in three, colchicine, conventional immunosuppressives and/or glucocorticoids were added in five, and topical eye drops were added in two patients, leading to remission of de novo manifestations in all patients. Conclusion: De novo manifestations were infrequent (4%) among BS patients treated with adalimumab. Of these, 57% were major organ involvement, mainly vascular involvement. None of the patients developed posterior uveitis.


  • Validation of the Behçet’s Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification

    by Yeliz Yagiz Ozogul, Yesim Ozguler, Sinem N Esatoglu, Didar Ucar, Ugur Uygunoglu, Zekayi Kutlubay, Vedat Hamuryudan, Gulen Hatemi

    Objective: Assessment of damage accrual over time is important for evaluating and comparing long-term results of treatment modalities and strategies. Retrospective studies may be useful for assessing long-term damage, especially in rare diseases. We aimed to validate Behçet’s Syndrome Overall Damage Index (BODI) for use in retrospective studies by evaluating its construct validity, reliability and feasibility in retrospectively collected data. Additionally, we aimed to determine missing items by evaluating Behçet’s syndrome patients with different types of organ involvement and long-term follow-up. Methods: We included 300 patients who had at least two clinic visits at 1-year intervals. The construct validity for use in retrospective trials was assessed by comparing BODI scores calculated from patient charts and during face-to-face visits. BODI was additionally scored using retrospective chart data by two different observers and by the same observer six months apart, in a blinded manner. The time for filling BODI was evaluated to assess feasibility. Additionally, damaged items that were missing from BODI were identified. Results: There was a good correlation between the retrospective and face-to-face evaluation of BODI (ICC 0.99; %95 CI 0.99–0.99). Inter-observer and intra-observer agreement were good (ICC 0.96 and 1, respectively). The main damage items that BODI did not capture were hypertension, liver failure, lung parenchymal involvement, glaucoma and lymphedema. Conclusion: BODI seems to be a reliable and feasible instrument for assessing damage in retrospective studies. Modifying BODI using the additional damage items identified in this study may make it an even better scale.


  • Open Access

    Folliculitis might be associated with pathergy-positivity in patients with Behçet syndrome

    by Zeynep Altan Ferhatoğlu, Dursun Dorukhan Altinişik, Ayşe Özdede, Defne Özkoca, Sabriye Güner, Kadir Atacan Yildiz, Zekayi Kutlubay, Emire Seyahi, Vedat Hamuryudan

    Pathergy test indicates nonspecific hyper-reactivity of the skin to aseptic trauma in Behçet syndrome (BS) and is considered as an adjunctive diagnostic test with a good specificity albeit with low sensitivity. We tested the hypothesis that a relationship exists between active clinical manifestations of BS and the pathergy-positivity when performed simultaneously. Pathergy test and detailed dermatologic examination were done in 105 BS patients (60M/45F); who were seen consecutively at the multi-disciplinary BS outpatient clinic in a single tertiary center. Information regarding demographic and clinical characteristics, pathergy test results at diagnosis, and details about treatment were obtained from patient charts. Disease activity was assessed using Behçet Disease Current Activity Form. Among 105 patients, 27 (25.7%) were pathergy-positive at the time of the study visit whereas 40.9% were pathergy-positive at the time of the diagnosis. There was no relation between pathergy test and patient age or disease duration, either. Pathergy-positivity was significantly more common in patients with folliculitis compared to those without folliculitis (40.7% vs 19.2%; P = .026). The test was also positive in all 3 patients with leg ulcers due to venous stasis. We found that among all skin-mucosa lesions only the presence of folliculitis was associated with pathergy positivity with statistical significance. It was also remarkable that the current pathergy was positive in all 3 patients with active leg ulcers but this finding warrants further studies because of the low patient numbers.


  • Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

    by Didar Ucar, Sinem Nihal Esatoglu, Emir Cerme, Bilge Batu-Oto, Vedat Hamuryudan, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Yılmaz Ozyazgan, Gulen Hatemi

    Experience with mycophenolate in uveitis due to Behçet syndrome (BS) is limited. Twelve patients with panuveitis or posterior uveitis who were started mycophenolate were included. Data on demographic characteristics, therapies, ocular attacks, and adverse events were extracted from patient charts. Seven patients with BS uveitis were prescribed mycophenolate for remission induction, of which 6 were refractory/intolerant to conventional immunosuppressives. Mycophenolate was combined with anti-TNFs in 3 patients, resulting in no further ocular attacks. Mycophenolate had to be stopped in the fourth patient due to adverse events. The remaining 3 patients continued to have ocular attacks and were switched to other agents without any drop in visual acuity. Among the 5 patients who were prescribed mycophenolate for maintenance, 2 were relapse free, but 3 experienced ocular attacks. One patient had an exacerbation of mucocutaneous lesions, and 2 experienced adverse events. Mycophenolate monotherapy may not be adequate for remission induction of refractory BS uveitis, but it can be a safe and effective alternative when combined with a biologic agent. It may also be an option for maintenance therapy.


  • Behçet's yndrome: one year in review 2023

    by Gülen Hatemi, Emire Seyahi, Izzet Fresko, Rosaria Talarico, Didar Uçar, Vedat Hamuryudan

    Review; Authors: G. Hatemi, E. Seyahi, I. Fresko, R. Talarico, D. Uçar, V. Hamuryudan